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Objective: We report the first case description of surgical aortic valve replacement
after percutaneous valve implantation.
Methods: An 87-year-old man with severe aortic stenosis who was rejected for surgi-
cal intervention underwent percutaneous valve implantation through a retrograde
femoral approach. The procedure was complicated by cardiogenic shock caused by
severe aortic insufficiency, leading to emergency surgical aortic valve replacement.
Results: The operative findings revealed the presence of commissural paravalvular
leaks and centrally malapposed leaflets. Surgical replacement was uneventful, and
the patient was discharged on day 30, despite a challenging postoperative course.
His follow-up at 1 year has been uneventful. This case illustrates that overdilatation
of the stent is not recommended because it might worsen central aortic insufficiency.
Moreover, the transapical route should be considered when the appropriately sized
prosthesis is unable to be inserted because of inappropriate vascular access. However,
despite an initial ‘‘prohibitive’’ surgical risk, surgical aortic valvular replacement after
percutaneous valve implantation could be easily performed.
Conclusion: Percutaneous heart valve implantation, which provides a larger surface
area than balloon valvotomy, can be offered to patients with cardiogenic shock and
severe comorbidities to improve their hemodynamic state and reduce their surgical
risk.
P
ercutaneous strategies for the treatment of severe aortic stenosis in nonsurgical
patients evolved over 20 years from balloon valvuloplasty to percutaneous
heart valve (PHV) implantation.1 Despite encouraging results, this technique
is still evolving, and each case provides a source of procedural improvement. We re-
port the first case description of a surgical aortic valve replacement after percutaneous
aortic valve implantation and discuss the findings revealed by this intervention.
Clinical Summary
An 87-year-old man with severe symptomatic aortic stenosis and in New York Heart
Association functional class 3 or 4 was transferred to our institution in October 2006
for aortic PHV implantation. He was deemed a nonsurgical candidate by 2 indepen-
dent surgeons because of his age and multiple comorbidities, which included previous
stroke, ischemic cardiomyopathy with a left ventricular ejection fraction (LVEF) of
24%, proximal occlusion of the left circumflex artery, atrial fibrillation with
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LVEF 5 left ventricular ejection fraction
PHC 5 percutaneous heart valve
pacemaker dependency, and a prior right hemicolectomy for
colon cancer. His logistic EuroSCORE was 22.78%. A suc-
cessful balloon aortic valvuloplasty had been performed 8
months prior, but his symptoms had recently recurred.
On admission, transthoracic echocardiographic analysis
revealed a severely calcified aortic valve with a valve area
of 0.4 cm2, a mean aortic pressure gradient of 46 mm Hg,
an aortic annulus diameter of 20 mm, a pulmonary artery sys-
tolic pressure of 60 mm Hg, and an LVEF of 25%. Aortic an-
giographic analysis with iliofemoral runoff and computed
tomographic scanning revealed severe calcification of the
distal aorta and proximal iliac arteries. The diameter of the
iliofemoral vessels did not exceed 8 mm. The patient was in-
cluded in the Registry of EndoVascular Implantation of
Valves in Europe (REVIVE) trial and was scheduled to re-
ceive a 23-mm Cribier–Edwards PHV (Percutaneous Valve
Technologies; Edwards LifeScience, Irvine, Calif) by using
a 22F delivery system through the right femoral artery.
The incision of the groin was performed after achievement
of local anesthesia, and the right femoral artery was catheter-
ized. Uneventful aortic valve predilatation with a 23-mm
Z-Med II (Numed, Cornwall, Canada) balloon through
a 14F sheath was performed. After progressive dilatation of
the right femoroiliac arteries with 16F to 22F dilators, the
23-mm Cribier–Edwards prosthesis was advanced to the
aortic valve and placed under rapid cardiac stimulation (200
beats/min). After this procedure, recovery of a satisfactory
blood pressure was only obtained with the use of inotropes
and vasopressors. Supra-aortic angiographic analysis subse-
quently showed severe aortic regurgitation (Figure 1). Postdi-
latation of the PHV with a 23-mm balloon was performed,
leading to a period of cardiac arrest requiring several minutes
of chest compressions. The patient was intubated, mechani-
cally ventilated, and transferred to the intensive care unit
with escalating vasopressor requirements. Although he was
extubated 6 hours later, he persisted with hemodynamic insta-
bility characterized by a diastolic blood pressure of 35mmHg
and oliguria. Repeat echocardiographic analysis confirmed
the presence of severe paravalvular insufficiency with 2 dis-
tinct jets and a smaller area ofmild central aortic insufficiency.
The aortic valve area was measured at 1.7 cm2 with a minimal
transvalvular gradient and an LVEF of 60% with inotropes.
Because of his poor prognosis and frank improvement of
cardiac function, after obtaining consent from the patient and
his family, surgical aortic valve replacement was attempted.
After a median sternotomy, the patient was started on car-
diopulmonary bypass. Anterograde and retrograde continu-
ous hot blood cardioplegia was used for myocardial698 The Journal of Thoracic and Cardiovascular Surgery c Sepprotection. Incision of the ascending aorta revealed a PHV
in perfect position on the aortic annulus with the coronary os-
tia free from occlusion (see video, online). Analysis of the na-
tive valve showed a major gap between the stent and the
commissure between the left and right coronary cusps and
a minor one between the stent and the commissure between
the left and noncoronary cusps (Figure 2). There was a small
central leak on the PHV caused by leaflet malapposition,
leading to central dehiscence. Nevertheless, the circular
Figure 1. Supra-aortic angiogram showing commissural paravalv-
ular leak (arrow).
Figure 2. Operative view demonstrating the presence of paravalv-
ular leaks on the commissures between the left and right coronary
cusps and between the left and noncoronary cusps (arrows). The
valve presents a geometric asymmetry of the 3 cusps, leading to
a dehisced prosthesis with a small central incompetence.tember 2008
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PHV was performed without difficulty by pulling the pros-
thesis with a Kelly forceps (Figure 3). The 3 native aortic
valve leaflets remained retracted in an open position because
of commissural and calcium cracking after repetitive balloon
inflation and stent deployment (Figure 4).
Resection of the cusps was problematic. The valve was
heavily calcified, and the successive balloon valvuloplasties
had disrupted numerous calcified nodules. The calcareous
fragments were carefully removed from the cusps, aortic an-
nulus, and mitral valve leaflets. Because of the risk of embo-
lization, the implantation site and left ventricular cavity were
extensively washed. The size of the aortic annulus was tested,
and a 23-mm Carpentier–Edwards Perimount valve (Ed-
wards LifeScience) was implanted uneventfully. After 85
minutes, the cardiopulmonary bypass was weaned while
the patient required 18 mg $ min21 $ m22 dobutamine and
0.7 mg $ min21 $ m22 norepinephrine. Hemostasis was diffi-
cult because of the antiplatelet treatment previously adminis-
tered (aspirin and clopidogrel).
The postoperative course was marked by 3 days of anuria
requiring dialysis after cardiogenic shock and contrast-
induced nephropathy. The patient was extubated, progres-
sively weaned off of inotropic support, and transferred out
of the intensive care unit after 8 days. Postoperative echocar-
diographic analysis revealed no aortic insufficiency, a mean
aortic gradient of 11 mm Hg, pulmonary artery systolic
pressure of 30 mm Hg, and an LVEF of 54%. The patient
was discharged from the hospital on day 30. He is still alive
1 year after the procedure with improved physical activity
and without recurrence of heart failure.
Discussion
Surgical aortic valve replacement has a very low mortality
and morbidity and is considered the gold standard for the
treatment of symptomatic aortic valve stenosis.2 Neverthe-
Figure 3. Percutaneous heart valve removal with a Kelly forceps.The Journal of Tholess, a nonnegligible cohort of patients is not referred to or
is rejected for surgical intervention because of their comor-
bidities. Most of these patients are considered to have an
‘‘unacceptable’’ high risk for cardiac surgery, as calculated
by using the Society of Thoracic Surgeons risk calculator
or logistic EuroSCORE. The development of PHV implanta-
tion appears to be a solution to treat these high-risk patients.
However, percutaneous valvular replacement still requires
large arterial sheaths that limit patient candidacy.
Aortic PHV sizing is guided by echocardiographic mea-
surement of the aortic annulus. Although this patient’s aortic
annulus diameter (20 mm) was compatible with a 23-mm
valve, early experience with PHV implantation has revealed
a higher rate of periprosthetic regurgitation with the use of the
23-mm valve when compared with the 26-mm valve, partic-
ularly in male patients. The 24F sheath, required for the
26-mm valve, has a 9-mm outer diameter. Its insertion would
have increased the risk of vascular damage caused by the
arterial calcification and the iliac artery’s minimal luminal
diameter (8 mm). PHV placement after achievement of local
anesthesia, as performed in our institution, appears advanta-
geous because it alerts the implanting physician of patient
discomfort during arterial dilation or sheath insertion, which
suggests arterial damage. Such an occurrence forces the op-
erating team to stop the procedure, re-evaluate the possibility
of placing a smaller valve, or seek an alternative placement
route. This has minimized the incidence of arterial dissection
or rupture.
During surgical intervention, we observed that the para-
valvular leaks found on the angiograms were predominantly
located on 2 of the 3 commissures of the native valve. Severe
valvular calcification limits the full circular expansion of the
delivery balloon catheter, adding to the degree of aortic insuf-
ficiency. Despite the rupture of numerous calcifications and
full balloon expansion, complete circumferential apposition
Figure 4. Operative view after removal of the percutaneous heart
valve showing the calcified cusps, which remained open because
of the rupture of the valve calcifications.racic and Cardiovascular Surgery c Volume 136, Number 3 699
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ways achieved. This phenomenon can lead to paravalvular
leaks and early prosthetic degeneration. The presence of ma-
jor paravalvular leaks has a noxious hemodynamic effect in
these fragile patients. The hypertrophied heart with diastolic
dysfunction is unable to cope with the resultant severe acute
aortic insufficiency, which leads to immediate hemodynamic
failure. Minor paravalvular insufficiencies, as are generally
observed in these procedures, are well tolerated because of
the improvement of myocardial contraction after significant
afterload reduction.
As seen after the aortotomy (Figure 2), the valve presented
geometric asymmetry in the 3 cusps leading to a central mal-
apposition of the valve leaflets. Central dehiscence is a well-
known mode of failure of surgically implanted bioprostheses
and is the only one that is age independent.3 This phenome-
non is generally related to an irregular distribution of the su-
tures. In our case this could be directly linked to overdilation
after the procedure of implantation or to an asymmetric stent
deployment caused by the presence of heavy calcifications
during the procedure.
The first-generation bovine stented pericardial valves
were marked by early failure related to the basal attachment
site of the cusps and the supporting stent. This was particu-
larly observed in the ‘‘alignment stitch’’ zone, which main-
tains proper position of the valve leaflets and their
apposition at each commissure.4 All improvement of the
prosthesis design to diminish paravalvular leaks or improve
the leaflet apposition could hopefully lead to an increase of
its durability. The discrepancy observed between the aortic
annulus and the size of the PHV delivery system required
in the patient supports the use of a transapical approach in
certain cases to avoid a mismatched prosthesis. Unfortu-
nately, this technique was unavailable at the time of implan-
tation.
It is important to note that despite an initial ‘‘prohibitive’’
surgical risk, surgical aortic valve replacement after percuta-
neous valve implantation was performed. The removal of the
PHV was simple, despite the impaction of the stent in the
cusps of the native valve. The radial force of the stent is easily
overcome, and nonexcessive tension is necessary to extract
the valve prosthesis within seconds. The disruption of the
calcifications might give rise to the only difficulty of this
operation. Indeed, the resection of the 3 cusps produces
innumerable numbers of fragments, which increase the risk
of embolization after aortic cross-clamp removal. Copious ir-
rigation is necessary to obtain a secure clean field before the
implantation of the new bioprosthesis. The low rate of stroke
observed during implantation of the PHV1 is probably due to
the capture of the disrupted calcifications by the stent.
In our patient a 25-mm tester valve seemed oversized, and
the 23-mm prosthesis fit perfectly in the native annulus after
extensive decalcification. Thus we replaced the 23-mm PHV
with a 23-mm Edwards Perimount valve. PHVs are sized by700 The Journal of Thoracic and Cardiovascular Surgery c Sepmeans of an echocardiographic measurement at the cusp in-
sertion point in the aortic annulus, and they are mounted on
a thin stent platform. The measurement obtained with the
valve tester reflects the diameter of the prosthesis and its cas-
ing, representing a different dimension. We must underline
that despite different designs, these valves present a similar
effective orifice area of 1.7 cm2.1,5 The resection of the cusps
and the annulus decalcification allowed the use of a larger-
profile prosthesis.
Despite severe comorbidities, hemodynamic compromise,
and a logistic EuroSCORE of 22.78%, the postoperative
course had complications that were easily managed. In pa-
tients with multiple comorbidities, the logistic Euroscore is
inaccurate and overestimates their surgical mortality rate,
thus limiting its usefulness.6 Clinical judgment is crucial
for rendering a surgical opinion and should take precedence
to risk models in this patient population. The use of risk cal-
culators should be used in clinical trials to unify a patient
population.7 In clinical practice their use complements clini-
cal judgment.
A PHV might be used as a bridge for cardiac surgery,
replacing balloon valvotomy, as suggested in the American
College of Cardiology/American Heart Association ‘‘2006
Guidelines for the management of patients with valvular
heart disease.’’2 As noted earlier, PHV implantation provides
a larger surface area than balloon valvuloplasty, which rarely
exceeds 1 cm2. PHV implantation can be offered to patients
with refractory pulmonary edema or cardiogenic shock to im-
prove their hemodynamic state and reduce their surgical risk.
Other patients with severe comorbidities that might limit their
survival could also benefit from this new device. The viabil-
ity of such algorithms remains to be demonstrated.
Conclusion
PHV implantation is at an early stage of development. The
encouraging results obtained with preliminary implantations
should not underestimate the complexities and tribulations
that arise during the development of new techniques. The
future of percutaneous procedures depends on the full collab-
oration between the cardiac surgeon, cardiologist, and anes-
thesiologist to manage these challenging patients.
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